Lo Ovral 28 Dosage
Medically reviewed by Drugs.com. Last updated on Feb 19, 2021.
Generic name: NORGESTREL 0.3mg, ETHINYL ESTRADIOL 0.03mg;
Dosage form: tablets
To achieve maximum contraceptive effectiveness, LO/OVRAL-28 (norgestrel and ethinyl estradiol tablets) must be taken exactly as directed and at intervals not exceeding 24 hours.
The dosage of LO/OVRAL-28 is one white tablet daily for 21 consecutive days, followed by one pink inert tablet daily for 7 consecutive days, according to prescribed schedule. It is recommended that LO/OVRAL-28 tablets be taken at the same time each day.
During The First Cycle of Use
The possibility of ovulation and conception prior to initiation of medication should be considered. The patient should be instructed to begin taking LO/OVRAL-28 on either the first Sunday after the onset of menstruation (Sunday Start) or on Day 1 of menstruation (Day 1 Start).
The patient is instructed to begin taking LO/OVRAL-28 on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (white) is taken that day. One white tablet should be taken daily for 21 consecutive days followed by one pink inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within 3 days following discontinuation of white tablets and may not have finished before the next pack is started. During the first cycle, contraceptive reliance should not be placed on LO/OVRAL-28 until a white tablet has been taken daily for 7 consecutive days and a non-hormonal back-up method of birth control should be used during those 7 days.
Day 1 start:
During the first cycle of medication, the patient is instructed to begin taking LO/OVRAL-28 during the first 24 hours of her period (day one of her menstrual cycle). One white tablet should be taken for 21 consecutive days, followed by one pink inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within 3 days following discontinuation of white tablets and may not have finished before the next pack is started. If medication is begun on day one of the menstrual cycle, no back-up contraception is necessary. If LO/OVRAL-28 tablets are started later than day one of the first menstrual cycle or postpartum, contraceptive reliance should not be placed on LO/OVRAL-28 tablets until after the first 7 consecutive days of administration, and a non-hormonal back-up method of birth control should be used during those 7 days.
After the first cycle of use
The patient begins her next and all subsequent courses of tablets on the day after taking her last pink tablet. She should follow the same dosing schedule: 21 days on white tablets followed by 7 days on pink tablets. If in any cycle the patient starts tablets later than the proper day, she should protect herself against pregnancy by using a non-hormonal back-up method of birth control until she has taken a white tablet daily for 7 consecutive days.
Switching from another hormonal method of contraception
When the patient is switching from a 21-day regimen of tablets, she should wait 7 days after her last tablet before she starts LO/OVRAL-28. She will probably experience withdrawal bleeding during that week. She should be sure that no more than 7 days pass after her previous 21-day regimen. When the patient is switching from a 28-day regimen of tablets, she should start her first pack of LO/OVRAL-28 on the day after her last tablet. She should not wait any days between packs. The patient may switch any day from a progestin-only pill and should begin LO/OVRAL-28 the next day. If switching from an implant or injection, the patient should start LO/OVRAL-28 on the day of implant removal or the day the next injection would be due. In switching from a progestin-only pill, injection, or implant, the patient should be advised to use a non-hormonal back-up method of birth control for the first 7 days of tablet-taking.
If spotting or breakthrough bleeding occurs
If spotting or breakthrough bleeding occurs, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician.
Risk of pregnancy if tablets are missed
While there is little likelihood of ovulation occurring if only one or two white tablets are missed, the possibility of ovulation increases with each successive day that scheduled white tablets are missed. Although the occurrence of pregnancy is unlikely if LO/OVRAL-28 is taken according to directions, if withdrawal bleeding does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out.
The risk of pregnancy increases with each active (white) tablet missed. For additional patient instructions regarding missed tablets, see the WHAT TO DO IF YOU MISS PILLS section in the DETAILED PATIENT LABELING below.
Use after pregnancy, abortion, or miscarriage
LO/OVRAL-28 may be initiated no earlier than day 28 postpartum in the nonlactating mother or after a second-trimester abortion due to the increased risk for thromboembolism (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS concerning thromboembolic disease). The patient should be advised to use a non-hormonal back-up method for the first 7 days of tablet-taking.
LO/OVRAL-28 may be initiated immediately after a first-trimester abortion or miscarriage. If the patient starts LO/OVRAL-28 immediately, back-up contraception is not needed.
More about Lo / Ovral-28 (ethinyl estradiol / norgestrel)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- 7 Reviews
- Drug class: contraceptives
- FDA Alerts (1)
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.